Shandong Boan Biotechnology Co., Ltd.
山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

VOLUNTARY ANNOUNCEMENT

CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)

The board of directors (the "**Board**") of Shandong Boan Biotechnology Co., Ltd. (the "**Company**") announces that China's Center for Drug Evaluation ("**CDE**") of the National Medical Products Administration (NMPA) has accepted the investigational new drug ("**IND**") application for BA1203, an antibody-cytokine prodrug targeting PD-1 and IL-2 pathways. The Company developed BA1203 as a next-generation immuno-oncology ("**IO**") therapy intended to treat multiple solid tumors. To the knowledge of the Company, BA1203 is poised to become the first masked PD-1/IL-2 antibody-cytokine prodrug retaining α-subunit binding activity to enter clinical trials in China.

IO therapies, led by PD-1/PD-L1 inhibitors, have become a cornerstone treatment method for malignancies. However, a significant proportion of patients still experience primary non-response, recurrence, or drug resistance. Previous meta-analyses have shown that PD-1/PD-L1 inhibitor monotherapy yields an overall objective response rate (ORR) of approximately 20%, with response rates varying significantly across tumor types and PD-L1 expression levels. These findings highlight the significant unmet clinical need with current immunotherapies.

IL-2 is a critical cytokine that promotes T-cell proliferation and restores T-cell function. However, traditional IL-2 therapies are limited by their narrow therapeutic window, non-selective activation of peripheral immune cells, and the risk of systemic toxicity. Consequently, achieving targeted delivery and selective activation of IL-2 within the tumor microenvironment ("**TME**") has become a key area of exploration for next-generation IO therapies.

BA1203 leverages the dual mechanism of action of a PD-1 antibody and an IL-2 cytokine, aiming to simultaneously achieve immune checkpoint blockade and localized immune activation within the TME. Through a masked design, the IL-2 prodrug selectively activates within the TME to amplify local anti-tumor immunity while minimizing cytokine activity in peripheral tissues to mitigate systemic toxicity risks. Concurrently, the molecule features a high-affinity, bivalent PD-1 targeting architecture, which enhances pathway blockade and enables precise delivery of IL-2 to PD-1-positive tumor-infiltrating T cells. In addition, BA1203 features a symmetric molecular design structure, which improves molecular stability and the controllability of the manufacturing process.

Preclinical studies show that BA1203 exhibits a differentiated profile in terms of PD-1 binding, immune pathway blockade, and immune activation within the TME. Notably, BA1203 demonstrated superior anti-tumor activity that significantly outperformed existing PD-1/PD-L1 antibodies across multiple tumor models where such checkpoint inhibitors were ineffective or exhibited limited activity. In tumor-bearing mouse models, BA1203 demonstrated superior efficacy compared to the competitor in the same class, while exhibiting a more favorable safety profile driven by tumor-dependent activation. Crucially, while enhancing localized intratumoral immune activation, BA1203 maintains low peripheral toxicity; studies involving cynomolgus monkeys demonstrate its favorable safety and tolerability profile.

BA1203 represents a key strategic initiative of the Company in developing next-generation IO therapies. Engineered with a symmetric molecular structure, BA1203 features high-affinity, bivalent PD-1 targeting coupled with a masked IL-2. The Company expects such architecture to deliver a superior efficacy and safety profile. The Company will accelerate the clinical development of BA1203 while further exploring its therapeutic potential as both a monotherapy and in combination with other treatment regimens.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua
Chairlady, Chief Executive Officer and Executive Director

Yantai, the People's Republic of China, 8 July 2026

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.